Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21411396 | 0.93 | CYP4F2 (0.53) | CYP4F2CYP4A11MAPTGAAALDH1A1 | |
| SCHEMBL31579906 | 0.92 | MMP9 (0.54) | CYP4F2CYP4A11MAPTGAAALDH1A1 | |
| SCHEMBL11674790 | 0.92 | RORC (0.52) | CYP4F2CYP4A11MAPTGAAALDH1A1 | |
| SCHEMBL11564250 | 0.92 | RORC (0.52) | CYP4F2CYP4A11MAPTGAAALDH1A1 | |
| SCHEMBL14379157 | 0.91 | CYP4F2 (0.47) | CYP4F2CYP4A11MAPTGAAALDH1A1 | |
| SCHEMBL27496248 | 0.91 | CYP19A1 (0.50) | CYP4F2CYP4A11MAPTGAAALDH1A1 | |
| SCHEMBL17112134 | 0.90 | CYP4F2 (0.45) | CYP4F2CYP4A11MAPTGAAALDH1A1 | |
| SCHEMBL6750339 | 0.89 | CYP4F2 (0.49) | CYP4F2CYP4A11MAPTGAAALDH1A1 | |
| SCHEMBL11038191 | 0.88 | MAPT (0.59) | CYP4F2CYP4A11MAPTGAAALDH1A1 | |
| SCHEMBL11038194 | 0.88 | MAPT (0.59) | CYP4F2CYP4A11MAPTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774805-B1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | SERVIER LAB (FR) | 2024-01-10 | — | — | EP | disclosed |
| CN-111936499-B | Heterobicyclic inhibitors of MAT2A and methods for treating cancer | 法国施维雅药厂 | 2023-09-19 | — | — | CN | disclosed |
| US-11524960-B2 | Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer | SERVIER PHARMACEUTICALS LLC (US) | 2022-12-13 | — | — | US | disclosed |
| CN-112915092-A | Combinations of AKT inhibitor compounds and abiraterone and methods of use | 基因泰克公司 | 2021-06-08 | — | — | CN | disclosed |
| US-20210115045-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | SERVIER PHARMACEUTICALS LLC | 2021-04-22 | — | — | US | disclosed |
| EP-3774805-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | Agios Pharmaceuticals, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-111936499-A | Heterobicyclic inhibitors of MAT2A and methods for treating cancer | 安吉奥斯医药品有限公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-111643504-A | Combinations of AKT inhibitor compounds and chemotherapeutic agents and methods of use | 基因泰克公司 | 2020-09-11 | — | — | CN | disclosed |
| WO-2019191470-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| US-10092567-B2 | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use | GENENTECH, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| CN-101801955-B | Pyrimidyl cyclopentanes as akt protein kinase inhibitors | ARRAY BIOPHARMA INC | 2013-05-08 | — | — | CN | disclosed |
| CN-102939290-A | 2,3 dihydro-1h-inden-1-yl- 2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor | PFIZER | 2013-02-20 | — | — | CN | disclosed |
| WO-2012135759-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ABIRATERONE, AND METHODS OF USE | GENENTECH, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012135781-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012135753-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE | GENENTECH, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012135750-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND VEMURAFENIB, AND METHODS OF USE | GENENTECH, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20110015204-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| CN-101801955-A | Pyrimidyl cyclopentanes as akt protein kinase inhibitors | ARRAY BIOPHARMA INC | 2010-08-11 | — | — | CN | disclosed |
| EP-2170863-A2 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009006567-A2 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115045-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | MAT2A, MAT2B, MAT1A | CYP4F2 824/4885CYP4A11 2929/4885MAPT 1127/4885 |
| US-10092567-B2 | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use | AKT1, AKT2, MTOR | CYP4F2 3710/4885CYP4A11 2074/4885MAPT 2521/4885 |
| US-11524960-B2 | Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer | MAT2A, MAT2B, MAT1A | CYP4F2 824/4885CYP4A11 2929/4885MAPT 1127/4885 |
| US-20110015204-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | CYP4F2 1063/4885CYP4A11 693/4885MAPT 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.